A Phase I, Multicenter, Open-Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 when Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Trial Profile

A Phase I, Multicenter, Open-Label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 when Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2014

At a glance

  • Drugs VAY 736 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 10 Oct 2013 Status changed from recruiting to discontinued, according to M.D. Anderson Cancer Center record.
    • 10 Oct 2013 New source identified and integrated: M.D. Anderson Cancer Center record.
    • 25 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top